Company expands strategic focus into one of oncology’s most urgent supportive-care challengesJericho, New York, April 02, 2026 (GLOBE NEWSWIRE) ...

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...

PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...

Two phase 3 randomized trials focused on evaluating the safety and efficiency of anamorelin to treat adult patients with advanced non-small cell lung cancer linked with weight loss and cachexia. In ...

Until recently, the root cause of cachexia was identified as the inflammatory mediators produced either by the tumour itself ...

Opportunities in the market include increasing demand for personalized treatments, advancements in muscle preservation therapies, and adoption of digital patient monitoring Cancer Cachexia Market ...

NORTHBROOK, Ill.--(BUSINESS WIRE)--Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, has closed a $10 million Series B funding. The ...

The investigational drug ponsegromab — which inhibits growth differentiation factor 15 (GDF-15), a cytokine elevated in cancer cachexia — increases weight, appetite, and physical activity in patients ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...

Cachexia, defined as a loss of body weight, fat, and muscle mass that occurs in patients with chronic diseases, including cancer, remains a notable clinical challenge. With limited viable treatment ...

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...